Last reviewed · How we verify
Denegyt (DECIMEMIDE)
Denegyt (generic name: DECIMEMIDE) is a drug. It is currently in Phase 2 development.
Denegyt works by modulating a specific molecular target to produce a therapeutic effect.
Denegyt (Decimemide) is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The lack of approved indications and patent status makes it challenging to assess its commercial viability.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DECIMEMIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have a specific lock that needs to be turned to work properly. Denegyt is a key that fits into this lock, allowing the cell to function correctly and potentially treating a disease or condition. This is a simplified explanation of how Denegyt works at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Denegyt CI brief — competitive landscape report
- Denegyt updates RSS · CI watch RSS
Frequently asked questions about Denegyt
What is Denegyt?
How does Denegyt work?
What is the generic name of Denegyt?
What development phase is Denegyt in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing